Mario Alberto Diaz, M.D.-Denial of Application, 70788-70793 [E6-20630]
Download as PDF
70788
Federal Register / Vol. 71, No. 234 / Wednesday, December 6, 2006 / Notices
submissions with the Secretary by
facsimile or electronic means only to the
extent permitted by section 201.8 of the
rules (see Handbook for Electronic
Filing Procedures, ftp://ftp.usitc.gov/
pub/reports/
electronic_filing_handbook.pdf).
Persons with questions regarding
electronic filing should contact the
Secretary (202–205–2000 or
edis@usitc.gov).
Any submissions that contain
confidential business information must
also conform with the requirements of
section 201.6 of the Commission’s Rules
of Practice and Procedure (19 CFR
201.6). Section 201.6 of the rules
requires that the cover of the document
and the individual pages be clearly
marked as to whether they are the
‘‘confidential’’ or ‘‘nonconfidential’’
version, and that the confidential
business information be clearly
identified by means of brackets. All
written submissions, except for
confidential business information, will
be made available in the Office of the
Secretary to the Commission for
inspection by interested parties.
The Commission may include some or
all of the confidential business
information submitted in the course of
this investigation in the report it sends
to the USTR and the President.
However, should the Commission
publish a public version of this report,
such confidential business information
will not be published in a manner that
would reveal the operations of the firm
supplying the information.
The public record for this
investigation may be viewed on the
Commission’s electronic docket (EDIS)
at https://edis.usitc.gov. Hearing
impaired individuals may obtain
information on this matter by contacting
the Commission’s TDD terminal on 202–
205–1810. Persons with mobility
impairments who will need special
assistance in gaining access to the
Commission should contact the Office
of the Secretary at 202–205–2000.
By order of the Commission.
Issued: November 30, 2006.
Marilyn R. Abbott,
Secretary to the Commission.
[FR Doc. E6–20671 Filed 12–5–06; 8:45 am]
PWALKER on PRODPC60 with NOTICES
BILLING CODE 7020–02–P
INTERNATIONAL TRADE
COMMISSION
[USITC SE–06–062]
Sunshine Act Meeting Notice
United
States International Trade Commission.
AGENCY HOLDING THE MEETING:
VerDate Aug<31>2005
16:03 Dec 05, 2006
Jkt 211001
TIME AND DATE:
December 15, 2006 at 11
a.m.
Room 101, 500 E Street SW.,
Washington, DC 20436. Telephone:
(202) 205–2000.
STATUS: Open to the public.
PLACE:
Matters To Be Considered
1. Agenda for future meetings: none.
2. Minutes.
3. Ratification List.
4. Inv. Nos. 701–TA–444–446 and
731–TA–1107–1109
(Preliminary)(Coated Free Sheet Paper
from China, Indonesia, and Korea)—
briefing and vote. (The Commission is
currently scheduled to transmit its
determination to the Secretary of
Commerce on December 15, 2006;
Commissioners’ opinions are currently
scheduled to transmit its determination
to the Secretary of Commerce on or
before December 22, 2006.).
5. Outstanding action jackets: none.
In accordance with Commission
policy, subject matter listed above, not
disposed of at the scheduled meeting,
may be carried over to the agenda of the
following meeting.
By order of the Commission.
Issued: December 4, 2006.
Marilyn R. Abbott,
Secretary to the Commission.
[FR Doc. 06–9578 Filed 12–4–06; 11:43 am]
BILLING CODE 7020–02–P
INTERNATIONAL TRADE
COMMISSION
[USITC SE–06–060]
Sunshine Act Meeting Notice
United
States International Trade Commission.
TIME AND DATE: December 12, 2006 at 11
a.m.
PLACE: Room 101, 500 E Street SW.,
Washington, DC 20436. Telephone:
(202) 205–2000.
STATUS: Open to the public.
AGENCY HOLDING THE MEETING:
Matters To Be Considered
1. Agenda for future meetings: none.
2. Minutes.
3. Ratification List.
4. Inv. No. 731–TA–891
(Review)(Foundry Coke from China)—
briefing and vote. (The Commission is
currently scheduled to transmit its
determination and Commissioners’
opinions to the Secretary of Commerce
on or before December 29, 2006.).
5. Outstanding action jackets: none.
In accordance with Commission
policy, subject matter listed above, not
disposed of at the scheduled meeting,
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
may be carried over to the agenda of the
following meeting.
By order of the Commission.
Issued: December 4, 2006.
Marilyn R. Abbott,
Secretary to the Commission.
[FR Doc. 06–9579 Filed 12–4–06; 11:43 am]
BILLING CODE 7020–02–P
INTERNATIONAL TRADE
COMMISSION
[USITC SE–06–061]
Sunshine Act Meeting Notice
United
States International Trade Commission.
TIME AND DATE: December 14, 2006 at 11
a.m.
PLACE: Room 101, 500 E Street SW.,
Washington, DC 20436. Telephone:
(202) 205–2000.
STATUS: Open to the public.
AGENCY HOLDING THE MEETING:
Matters To Be Considered
1. Agenda for future meetings: none.
2. Minutes.
3. Ratification List.
4. Inv. Nos. AA1921–197, 701–TA–
319, 320, 325–327, 348, and 350); and
731–TA–573, 574, 576, 578, 582–587,
612, and 614–618 (Second Review)
(Certain Carbon Steel Products from
Australia, Belgium, Brazil, Canada,
Finland, France, Germany, Japan, Korea,
Mexico, Poland, Romania, Spain,
Sweden, Taiwan, and the United
Kingdom)—briefing and vote. (The
Commission is currently scheduled to
transmit its determination and
Commissioners’ opinions to the
Secretary of Commerce on or before
January 17, 2007.).
5. Outstanding action jackets: none.
In accordance with Commission
policy, subject matter listed above, not
disposed of at the scheduled meeting,
may be carried over to the agenda of the
following meeting.
By order of the Commission.
Issued: December 4, 2006.
Marilyn R. Abbott,
Secretary to the Commission.
[FR Doc. 06–9580 Filed 12–4–06; 11:43 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Mario Alberto Diaz, M.D.—Denial of
Application
On June 27, 2005, the Deputy
Assistant Administrator, Office of
E:\FR\FM\06DEN1.SGM
06DEN1
PWALKER on PRODPC60 with NOTICES
Federal Register / Vol. 71, No. 234 / Wednesday, December 6, 2006 / Notices
Diversion Control, Drug Enforcement
Administration, issued an Order to
Show Cause to Mario Alberto Diaz, M.D.
(Respondent) of Miami, Florida. The
Show Cause Order proposed to deny
Respondent’s pending application for a
DEA Certificate of Registration as a
practitioner, on the ground that granting
Respondent a registration would be
inconsistent with the public interest.
See Show Cause Order at 1; see also 21
U.S.C. 824(a)(4), id. § 823(f).
More specifically, the Show Cause
Order alleged that in May 2003,
Respondent, who had previously been
registered as a practitioner, entered into
a contract with Pharmacom, an Internet
pharmacy, under which he agreed to
issue prescriptions online. Show Cause
Order at 5. The Show Cause Order
alleged that Respondent issued
approximately 100 prescriptions per
day, and that Respondent admitted
having issued approximately twenty to
twenty-five thousand prescriptions
during the period of his employment
with Pharmacom. See id.
The Show Cause Order further alleged
that Respondent issued prescriptions for
controlled substances based on
questionnaires submitted by customers
over the Internet. See id. The Show
Cause Order alleged that the
questionnaire solicited from the
customer information regarding the
drugs the customer wished to purchase
and obtained the customer’s payment
information and was then electronically
transmitted to Respondent. See id. The
Show Cause Order alleged that based on
the questionnaire, Respondent would
issue a prescription for a controlled
substance and that the principal drugs
he prescribed were hydrocodone, a
Schedule III controlled substance, and
Valium, a Schedule IV controlled
substance. See id.
The Show Cause Order also alleged
that Respondent never saw the
customers and did not perform a
physical exam on them, that he did not
have a pre-existing doctor-patient
relationship with them, and that he did
not create or maintain patient records
for them. See id. The Show Cause Order
further alleged that Respondent never
consulted with the customers’ primary
care physicians or obtained from them
the customers’ medical records, and that
the only information he reviewed was
the questionnaires submitted by the
customers. See id. at 5–6.
The Show Cause Order additionally
alleged that many of the prescriptions
written by Respondent were for minors.
See id. at 6. The Show Cause Order also
alleged that during its investigation of
Pharmacom, the Iowa Board of
Pharmacy contacted approximately 20
VerDate Aug<31>2005
16:03 Dec 05, 2006
Jkt 211001
customers who had received
prescriptions for controlled substances
that were issued by Respondent. See id.
The Show Cause Order alleged that each
of these customers told investigators
that before receiving controlled
substances, they had had no contact
with Respondent other than by e-mail.
Id. The Show Cause Order thus
concluded by alleging that Respondent
was ‘‘responsible for the diversion of
large quantities of controlled
substances,’’ and that he had
‘‘indiscriminately dispensed large
volumes of controlled substances to
persons’’ he had never seen or
physically examined. Id.
On July 15, 2005, the Show Cause
Order was served on Respondent by
certified mail as evidenced by the
Return Receipt Card. Thereafter, on July
23, 2005, Respondent submitted a letter
to me in which he waived his right to
a hearing and submitted a written
statement setting forth his position on
the matters of fact and law involved. See
21 CFR 1301.43(c). The investigative file
was then forwarded to me for final
agency action.
Based on Respondent’s letter to me, I
conclude that Respondent has waived
his right to a hearing. Moreover, having
considered the record as a whole
including Respondent’s statement, I
conclude that granting Respondent’s
application for a new registration would
be inconsistent with the public interest
and make the following findings.
Findings
Respondent, a medical doctor with a
specialty in anesthesiology, formerly
held a DEA certificate of registration as
a practitioner under which he was
authorized to prescribe Schedule II
through Schedule V controlled
substances. On May 20, 2004,
Respondent surrendered his registration
during the execution of a search warrant
at his residence/registered location,
which was located in Miami, Florida.
On September 12, 2003, two DEA
Diversion Investigators from the Des
Moines, Iowa office, DEA Task Force
Officers, and investigators from the Iowa
Board of Pharmacy Examiners executed
a federal search warrant at the Union
Family Pharmacy, 2541 Central Avenue,
Dubuque, Iowa. The search was
initiated based on information that the
Union Family Pharmacy was engaged in
filling purported prescriptions that it
downloaded from an Internet site and
that it distributed the drugs to persons
nationwide.
During the search, investigators seized
approximately twenty thousand
prescriptions that the pharmacy had
filled and dispensed from March 2003
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
70789
through September 12, 2003, the date
the warrant was executed. Of these
twenty thousand prescriptions,
approximately five thousand of them
had been filled and dispensed on behalf
of Pharmacom. All of the Pharmacom
prescriptions were filled between
August 18, 2003, and September 12,
2003.
The investigation determined that
Pharmacom was located in Miami,
Florida, and that it owned the domain
name Buymeds.com and operated the
Web site https://www.buymeds.com.
Approximately 1,240 of the controlled
substance prescriptions downloaded by
Union Family Pharmacy from the
Pharmacom web site and filled by the
pharmacy were issued by Respondent.
Because of unusual banking activity,
Pharmacom had previously come to the
attention of the Internal Revenue
Service (IRS) and, on September 2,
2003, two IRS special agents
interviewed Mr. Orlando Birbragher,
Pharmacom’s President and CEO.
During the interview, the IRS special
agents determined that Pharmacom
operated multiple on-line pharmacy
Web sites including Buymeds.com. The
interview determined that Pharmacom’s
customers submitted on-line
questionnaires to purchase Schedule III
and IV controlled substances, and that
Pharmacom’s doctors evaluated the
questionnaires to determine whether to
approve or reject the order.
Pharmacom’s doctors did not, however,
conduct a physical exam of the
customer. Instead, the questionnaires
required the patient to indicate whether
they had been examined by a physician
within the past year. Mr. Birbragher
further maintained that Pharmacom’s
doctors contacted the customers and
their physicians when evaluating the
questionnaires. Those prescriptions
which were approved were then sent to
a pharmacy, which filled the
prescriptions and shipped them to the
customers. Pharmacom paid both the
doctor who issued the prescription and
the pharmacy which filled it.
Mr. Birbragher told the IRS agents that
Respondent had started working for
Pharmacom in March 2003.
Respondent’s duties involved reviewing
the questionnaires and determining
whether a prescription should be
issued. Pharmacom initially paid
Respondent $20 for evaluating a request
for a new prescription and $10 for
evaluating a request for a refill. Because
of the volume of business it attracted,
Pharmacom subsequently cut its
payment rates in half. Even at this
reduced payment rate, Pharmacom paid
Respondent $218,586 between April
and August 2003. Mr. Birbragher further
E:\FR\FM\06DEN1.SGM
06DEN1
PWALKER on PRODPC60 with NOTICES
70790
Federal Register / Vol. 71, No. 234 / Wednesday, December 6, 2006 / Notices
told the IRS agents that Respondent
used physician assistants (PA’s) to assist
him in evaluating the patient
questionnaires. Mr. Birbragher did not
know, however, whether Respondent or
the PA’s actually reviewed the
questionnaires.
Thereafter, one of the DIs reviewed
prescription data obtained during the
search of the Union Family Pharmacy.
More specifically, the DI reviewed the
prescription data that the pharmacy
downloaded from the buymeds.com
website and filled on September 7,
2003. On that date, the pharmacy filled
583 Buymeds’ prescriptions. Of the 583
prescriptions, only 29 (4.9%) were for
non-controlled substances. The
remaining prescriptions were for
controlled substances such as
hydrocodone, codeine, propoxyphene,
and Ambien (zolpidem). Respondent
issued 146 of the 583 prescriptions that
were filled that day. While the
investigative file does not indicate how
many of these prescriptions were for
controlled substances, even if
Respondent issued all of the noncontrolled substance prescriptions, he
still would have issued 117 controlled
substance prescriptions that were filled
on that day.1
On May 20, 2004, investigators
executed a search warrant at
Respondent’s residence in Miami. While
Respondent was not home when the
search commenced, his son contacted
him by cell phone. Respondent spoke
with a DEA Special Agent and agreed to
return to his residence. Upon his return,
a DI and IRS special agent interviewed
him.
Respondent told the investigators that
he began working for Pharmacom in
April 2003 and quit in November 2003.
Respondent stated that another
physician had told him about
Pharmacom’s business and had
recommended him to Marshall Kanner,
one of the owners. Thereafter,
Respondent interviewed with Kanner
for a position with Pharmacom. Kanner
told him that the position would
involve authorizing medication over the
Internet to patients who were seeing or
had seen a doctor in the past year.
Respondent claimed that he expressed
to Kanner his concerns regarding
prescribing medicine in this manner,
but Kanner told him it was legal.
According to Respondent, Kanner also
told him he could authorize
prescriptions for customers throughout
the United States.
1 A further analysis of the computer data seized
during the search of the Union Family Pharmacy
found that Respondent issued 1,240 prescriptions
for controlled substances during the period August
18, 2003, through September 12, 2003.
VerDate Aug<31>2005
16:03 Dec 05, 2006
Jkt 211001
Respondent told the investigators that
customers would contact Pharmacom
through the Internet and fill out a
questionnaire provided by it.
Pharmacom then assigned a list of
patients to Respondent. Respondent’s
job was to review the questionnaires
and then interview the customers either
by telephone or e-mail to determine
whether the customers were eligible to
receive the drug they requested.
Respondent stated to the investigators
that he told Pharmacom that he was
only willing to review 100 customers a
day and that he did not issue
prescriptions to ten to twenty-five
percent of the customers. Respondent
also told the investigators that he
reviewed approximately 40 to 50 refill
prescriptions a day and that he made as
much as $14,000 a week.
Respondent further told the
investigators that he never saw any of
the customers and that he never
developed a doctor/patient relationship
with any of them as everything was
done either via the Internet or by
telephone. According to the DI’s report,
Respondent admitted that the
information provided by the customers
was never verified and that when he
interviewed customers by telephone, he
could not verify whom he was talking
to.
When the DI asked Respondent
whether he knew it violated the law to
issue a prescription for a controlled
substance without having a legitimate
doctor/patient relationship, Respondent
did not give a specific answer. Instead,
Respondent asserted that whenever he
questioned the legality of the practice,
Kanner or Birbragher assured him that
it was legal. When the DI reminded
Respondent that he was the doctor,
Respondent stated, ‘‘Yes, I know that.’’
Respondent also told the investigators
that he quit Pharmacom because
sometime in September or October
2003, Birbragher told him that all
customers would have to receive a
physical exam and that he did not agree
with this policy. When questioned as to
the basis of his disagreement,
Respondent became vague and evasive
and would not specifically answer the
question. Towards the end of the
interview, Respondent was also advised
by the DI that having surrendered his
DEA registration, he was not authorized
to handle controlled substances in any
manner and could not possess,
dispense, administer or prescribe them.
Subsequently, on September 14, 2004,
Respondent agreed to undergo a proffer
interview at the DEA Miami field office.
During the interview, at which he was
represented by counsel, Respondent
stated that he was currently employed at
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
a cosmetic surgery center where he
provided anesthesia services even
though he had previously surrendered
his DEA registration.
During this interview, Respondent
asserted that he had researched the DEA
w Web site and could not find any
statute indicating that prescribing over
the Internet ‘‘could not be done.’’
Respondent further stated that he
thought the practice was similar to that
in an emergency room where the
patients are ‘‘unknown’’ to the
physician. Respondent again
maintained that he had contacted
Kanner to determine whether the
practice was legal and had been told by
Kanner that Pharmacom’s attorneys had
‘‘stated that it was legal.’’ Respondent
further stated that when he met with
Kanner and Birbragher, they told him
‘‘they were licensed in all states and
[that] he could make a huge amount of
money.’’
Respondent further admitted that
while he limited himself to 100
‘‘patients’’ per day, a general
practitioner would normally see thirty
to forty patients per day. Respondent
asserted that the only difference
between his activities and that of a
general practitioner was that a ‘‘general
practitioner sees the patient.’’
Respondent added that he would review
the medical history provided by the
customer and such other information as
the customer’s location, age, weight,
height, and previous and current
medications. Later in this interview,
Respondent admitted that he ‘‘felt
uncomfortable with the number of
patients’’ he was assigned, and that
when he telephoned patients, ‘‘some
appeared to be druggies.’’ Respondent
also stated that as time went on, he ‘‘felt
people were ordering medications for
habits or entertainment,’’ and that the
‘‘types of people ordering were getting
worse and worse.’’
Respondent admitted that the
customers submitted requests for
specific drugs, but that he would ‘‘never
ask a patient what drug they wanted’’
because doing so would be contrary to
‘‘good medical practice.’’ He further
stated that the ‘‘best professional care
would be face to face.’’ He also claimed
that he had quit because the physical
examinations that Pharmacom had
started providing were incomplete.
Respondent admitted that some
customers requested multiple drugs
such as hydrocodone and alprazolam.
Respondent also stated that he approved
between twenty and twenty-five
thousand prescriptions during the
period of his association with
Pharmacom and that the highest number
of prescriptions he authorized in a day
E:\FR\FM\06DEN1.SGM
06DEN1
PWALKER on PRODPC60 with NOTICES
Federal Register / Vol. 71, No. 234 / Wednesday, December 6, 2006 / Notices
was about 200. In response to a question
regarding the danger of prescribing
medication without establishing a
doctor/patient relationship, Respondent
stated that the ‘‘potential for killing
people can happen in a hospital,’’ but
that ‘‘a bigger potential [exists] over the
Internet.’’
In his written statement responding to
the Show Cause Order, Respondent
asserted that he ‘‘attempted to perform
my medical functions in a professional
and ethical manner.’’ Respondent
further stated that he ‘‘did call the
patient to evaluate them for their
prescriptions,’’ and that he ‘‘denied a
high percentage of the prescriptions
requested.’’
Respondent asserted that he searched
the websites of both DEA and the
Florida Department of Health to see if
there were ‘‘any laws that made this
business illegal.’’ Respondent also
stated that Pharmacom’s owners had
‘‘fooled [him] into thinking that their
business was legal’’ and that he ‘‘would
never knowingly violate any laws.’’
Respondent further asserted that he was
unaware of the statements of DEA, the
American Medical Association, the
Federation of State Medical Boards, the
Food and Drug Administration, and the
National Association of Boards of
Pharmacy (all of which were recited in
the Show Cause Order) and all of which
discuss the illegality and/or impropriety
of prescribing over the Internet without
establishing a bona-fide doctor-patient
relationship.
Respondent contended that as an
anesthesiologist he had rarely written
prescriptions and that while he ‘‘knew
that a patient-doctor relationship had to
be established,’’ he ‘‘honestly believed
that having a patient fill out a
questionnaire about their health and
another dedicated section related to the
medication they were requesting would
fulfill this criteria.’’ Respondent also
maintained that he ‘‘would question the
patient about any previous prescriptions
for the medication they were then
requesting,’’ and that ‘‘[a] very large
percentage of them had already been
prescribed the medication by their
family physician.’’ Respondent further
stated that he ‘‘did call a few of their
physicians in cases I suspected of
problems.’’
In his written statement, Respondent
added that he resigned when he became
aware ‘‘that a physical examination was
needed to write a prescription.’’
Respondent also stated that he ‘‘will
never work for any endeavor of this type
ever again.’’ Respondent concluded by
stating that he ‘‘accept[ed] that the
selling of medications over the Internet
is not correct and that a prescription
VerDate Aug<31>2005
16:03 Dec 05, 2006
Jkt 211001
should not be written without a
physical examination.’’
I further take official notice of the fact
that on May 17, 2006, the Florida
Department of Health issued an order
imposing an emergency suspension of
Respondent’s state medical license. That
order remains in effect.
Discussion
Section 303(f) of the Controlled
Substances Act provides that an
application for a practitioner’s
registration may be denied upon a
determination ‘‘that the issuance of such
registration would be inconsistent with
the public interest.’’ 21 U.S.C. 823(f). In
making the public interest
determination, the Act requires the
consideration of the following factors:
(1) The recommendation of the appropriate
State licensing board or professional
disciplinary authority.
(2) The applicant’s experience in
dispensing * * * controlled substances.
(3) The applicant’s conviction record under
Federal or State laws relating to the
manufacture, distribution, or dispensing of
controlled substances.
(4) Compliance with applicable State,
Federal, or local laws relating to controlled
substances.
(5) Such other conduct which may threaten
the public health and safety.
Id.
‘‘[T]hese factors are * * * considered
in the disjunctive,’’ Robert A. Leslie,
M.D., 68 FR 15227, 15230 (2003). I ‘‘may
rely on any one or combination of
factors, and may give each factor the
weight [I] deem[] appropriate in
determining whether * * * an
application for registration [should be]
denied.’’ Id. Moreover, case law
establishes that I am ‘‘not required to
make findings as to all of the factors.’’
Hoxie v. DEA, 419 F.3d 477, 483 (6th
Cir. 2005); see also Morall v. DEA, 412
F.3d 165, 173–74 (D.C. Cir. 2005).
In this matter, I conclude that
multiple grounds support the denial of
Respondent’s application. Specifically,
Respondent currently lacks authority
under Florida law to practice medicine
and therefore is not entitled to a DEA
registration. Moreover, even if the State
of Florida were to rescind its order of
emergency suspension, my analysis of
several other factors also demonstrates
that granting his application would be
inconsistent with the public interest.
Factor One—The Recommendation of
the State Licensing Board
It has long been recognized that
‘‘[a]gencies may take official notice of
facts at any stage in a proceeding—even
in the final decision.’’ U.S. Dept. of
Justice, Attorney General’s Manual on
PO 00000
Frm 00058
Fmt 4703
Sfmt 4703
70791
the Administrative Procedure Act 80
(1947) (Wm. W. Gaunt & Sons, Inc.,
Reprint 1979). Therefore, pursuant to 5
U.S.C. 556(e) and 21 CFR § 1316.59(e),
I hereby take official notice of the fact
that on May 17, 2006, the Florida
Department of Health issued an order
imposing an emergency suspension of
Respondent’s state medical license.2
Respondent is therefore without
authority under state law to handle
controlled substances in the state in
which he intends to practice medicine.
Our precedents have repeatedly
construed the Controlled Substances
Act (CSA) as precluding DEA from
issuing a registration to an applicant
who lacks authority to handle
controlled substances in the state where
the applicant practices medicine. See 21
U.S.C. 802(21) & 823(f); see also George
Thomas, 64 FR 15811, 15812 (1999);
Robert E. Hales, 52 FR 17646 (1987).
Moreover, denial of an application is
appropriate even ‘‘when a State license
has been suspended, but [there is] a
possibility of future reactivitation.’’
Alton E. Ingram, Jr., 69 FR 22562 (2004).
Therefore, I conclude that Respondent’s
lack of state authority is reason alone to
deny his application for a registration.
But because the Florida Department of
Health’s order is not a final decision and
may be rescinded, an analysis of
Respondent’s conduct as charged in the
Show Cause Order and his defenses is
warranted.
Factors Two and Four—Respondent’s
Experience in Dispensing Controlled
Substances and His Record of
Compliance With Applicable Laws
The CSA’s implementing regulations
state that for ‘‘[a] prescription for a
controlled substance to be effective [it]
must be issued for a legitimate medical
purpose by an individual practitioner
acting in the usual course of his
professional practice.’’ 21 CFR
1306.04(a). This regulation further
provides that ‘‘[a]n order purporting to
be a prescription issued not in the usual
course of professional treatment * * *
is not a prescription within the meaning
and intent of * * * 21 U.S.C. 829 * * *
and the person * * * issuing it, shall be
subject to the penalties provided for
2 In accordance with the Administrative
Procedure Act and DEA’s regulations, Respondent
is ‘‘entitled on timely request, to an opportunity to
show to the contrary.’’ 5 U.S.C. 556(e). See also 21
CFR 1316.59(e). DEA’s regulations contain no
provision for requesting reconsideration of a final
order. See Robert A. Leslie, M.D., 60 FR 14004,
14005 (1995). To allow Respondent the opportunity
to refute the facts of which I am taking official
notice, publication of this final order shall be
withheld for a fifteen-day period, which shall begin
on the date of service by placing this order in the
mail.
E:\FR\FM\06DEN1.SGM
06DEN1
PWALKER on PRODPC60 with NOTICES
70792
Federal Register / Vol. 71, No. 234 / Wednesday, December 6, 2006 / Notices
violations of the provisions of law
relating to controlled substances.’’ Id.
As the Supreme Court has recognized,
the CSA reflects Congress’s ‘‘intent to
limit a registered physician’s dispensing
authority to the course of his
professional practice.’’ United States v.
Moore, 423 U.S. 122, 140 (1975). The
Court has further explained that the
CSA ‘‘reflect[s] the intent of Congress to
confine authorized medical practice
within accepted limits.’’ Id. at 141–42.
Thus, in Moore, the Court upheld a
criminal conviction of a physician for
knowingly or intentionally distributing
controlled substances in violation of the
CSA, explaining that the physician’s
‘‘conduct exceeded the bounds of
professional practice’’ when the
physician prescribed controlled
substances and ‘‘gave inadequate
physical examinations or none at all.’’
Id. at 142–43.
The evidence in this case establishes
that Respondent repeatedly acted
outside the course of professional
practice and violated the CSA.
Respondent, while contracted to
Pharmacom, issued between twenty and
twenty-five thousand prescriptions to
persons with whom he had no bonafide
doctor-patient relationship. While the
investigative file does not establish the
exact number of controlled substance
prescriptions issued by Respondent, the
analysis of the 583 Buymeds.com
prescriptions filled by Union Family
Pharmacy on September 7, 2003,
establishes that at least 117 (out of a
total of 143) prescriptions issued by
Respondent and filled on that date were
for a controlled substance.3
Furthermore, the analysis of the
prescriptions filled by the Union Family
Pharmacy for Pharmacom between
August 18, 2003, and September 12,
2003, shows that Respondent issued
1240 controlled substance prescriptions.
Given that this represents only a small
portion of the period during which
Respondent was engaged with
Pharmacom, it is reasonable to infer that
Respondent issued many more
prescriptions for controlled substances.
Respondent issued the prescriptions
notwithstanding that he did not perform
a physical exam and had no face-to-face
interaction with Pharmacom’s
customers. While Respondent
maintained that he called or contacted
via e-mail the customers ‘‘on a regular
basis’’ to discuss their questionnaires
and denied some percentage of the
requests, Respondent admitted in the
interviews that there was generally no
3 The
investigative file does not establish the
precise date that Respondent issued these
prescriptions.
VerDate Aug<31>2005
16:03 Dec 05, 2006
Jkt 211001
way to verify the information provided
by the customers.4
Furthermore, while Respondent
asserts that he asked Pharmacom’s
owners about the legality of issuing
Internet prescriptions (who assured him
that the practice was lawful), there were
numerous reasons to question its
legality. For example, customers were
not required to submit any
documentation (other than the
questionnaire) regarding a medical
condition that would demonstrate the
need for a drug.5 Moreover, Respondent
did not review the customer’s
questionnaires and choose a drug to
prescribe based on his ‘‘diagnosis’’ of
the customer’s medical condition.
Rather, it was the customer who
requested a specific drug. Respondent
admitted, however, that he would
‘‘never ask a patient what drug they
wanted’’ because doing so would be
contrary to ‘‘good medical practice.’’
Finally, Respondent should have
questioned why Pharmacom’s
customers did not submit prescriptions
issued by their own doctors but rather
required that prescriptions be issued by
him and the other Pharmacom doctors.
Indeed, Respondent admitted that when
he telephoned patients, ‘‘some appeared
to be druggies,’’ and that as time went
on he ‘‘felt people were ordering
medications for habits or
entertainment.’’ In short, Respondent
had numerous indications that issuing
prescriptions in this manner ‘‘exceeded
the bounds of professional practice,’’
Moore, 423 U.S. at 142, and violated
federal law notwithstanding the
comments of Pharmacom’s owners.
Respondent maintains that he visited
the DEA and Florida Department of
Health Web sites but could find no
information that the practice of Internet
prescribing was illegal. As for his effort
to find information on the issue at the
DEA Web site, Respondent must not
have looked very hard. On April 27,
2001, DEA published a Notice in the
Federal Register entitled ‘‘Dispensing
and Purchasing Controlled Substances
over the Internet.’’ See 66 FR 21181. To
the extent DEA was required to give
notice of this policy statement,
publication in the Federal Register is all
that was necessary to comply with the
Administrative Procedure Act. See
4 I note, however, that Respondent does not
contend that he actually contacted every patient.
Moreover, the assembly line nature of his activity
begs the question of what Respondent did when a
customer did not answer the phone or failed to
timely call him back or respond to his e-mail.
5 This is not to suggest that Respondent would
have acted lawfully if he had issued prescriptions
on the basis of medical reports submitted directly
to him by customers.
PO 00000
Frm 00059
Fmt 4703
Sfmt 4703
5 U.S.C. 552(a)(1)(D). DEA, however,
took the further step of posting this
policy statement on the Office of
Diversion Control’s Web page and the
document is easily found by using the
Web page’s search engine.
The purpose of the Notice was ‘‘to
provide guidance to prescribers * * *
and the public concerning the
application of current laws and
regulations as they relate to the use of
the Internet for dispensing [and]
purchasing * * * controlled
substances.’’ Id. The Notice further
explained that ‘‘[w]ith the advent of
Internet pharmacies, DEA registrants
and the public have asked how these
Internet pharmacies fit into the
requirements that currently exist for the
prescribing and dispensing of controlled
substances.’’ Thus, DEA issued this
policy statement, which was based on
the application of existing law to the
new circumstances that arose with the
emergence of the Internet as a
mechanism to engage in commerce.
The Notice expressly addressed the
potential illegality under existing law of
prescribing a controlled substance based
on an on-line questionnaire. After
noting the regulation pertaining to the
purpose of a prescription, see 21 CFR
1306.04, the Notice explained that
‘‘[u]nder Federal and state law, for a
doctor to be acting in the usual course
of professional practice, there must be a
bona fide doctor/patient relationship.’’
66 FR at 21182. The Notice further
observed that:
many state authorities, with the endorsement
of medical societies, consider the existence of
the following four elements as an indication
that a legitimate doctor/patient relationship
has been established:
• A patient has a medical complaint
• A medical history has been taken
• A physical examination has been
performed; and
• Some logical connection exists between
the medical complaint, the medical history,
the physical examination, and the drug
prescribed.
Id. at 21182–83.
The Notice thus concluded that
‘‘[c]ompleting a questionnaire that is
then reviewed by a doctor hired by the
Internet pharmacy could not be
considered the basis for a doctor/patient
relationship. * * * It is illegal to
receive a prescription for a controlled
substance without the establishment of
a legitimate doctor/patient relationship,
and it is unlikely for such a relationship
to be formed through Internet
correspondence alone.’’ 6 Id. at 21183.
6 As the Notice explained, ‘‘[a] consumer can
more easily provide false information in a
questionnaire than in a face-to-face meeting with a
doctor.’’ Id. at 21183.
E:\FR\FM\06DEN1.SGM
06DEN1
Federal Register / Vol. 71, No. 234 / Wednesday, December 6, 2006 / Notices
PWALKER on PRODPC60 with NOTICES
The Notice further stated that doctors
who issued prescriptions without
establishing a legitimate doctor/patient
relationship could be subjected ‘‘to
criminal, civil, or administrative
actions,’’ and that ‘‘[f]or DEA registrants
administrative action may include the
loss of their DEA registration.’’ Id. Thus,
contrary to Respondent’s suggestion that
no information was publicly available
regarding the potential illegality of the
practice, DEA had given fair warning
that prescribing a controlled substance
based on an on-line questionnaire and
without conducting a physical exam
could be deemed a violation of the
CSA’s longstanding requirement that a
prescription must be issued for a
legitimate medical purpose. DEA also
warned that issuing a prescription
without such a purpose could subject a
physician to criminal, civil and
administrative proceedings.
Moreover, in April 2002, the
Federation of State Medical Boards
adopted its model guidelines for the use
of the Internet in medical practice.
Section Five of this document states that
‘‘[a] documented patient evaluation,
including history and physical
evaluation adequate to establish
diagnoses and identify underlying
conditions and/or contra-indications to
the treatment recommended/provided,
must be obtained prior to providing
treatment, including issuing
prescriptions, electronically or
otherwise.’’ Federation of State Medical
Boards of the U.S., Inc., Model
Guidelines for the Appropriate Use of
the Internet in Medical Practice 5 (2002)
(emphasis added).
The guidelines further state that
‘‘[t]reatment and consultation
recommendations made in an online
setting, including issuing a prescription
via electronic means, will be held to the
same standards of appropriate practice
as those in traditional (face-to-face)
settings.’’ Id. Finally, the guidelines
state that ‘‘[t]reatment, including issuing
a prescription, based solely on an online
questionnaire or consultation, does not
constitute an acceptable standard of
care.’’ Id.
Thus, while Respondent may have
lacked actual knowledge of DEA’s
interpretation of the CSA and the
position of other entities involved in the
regulation of his profession, I conclude
The Notice also discussed some Internet sites
which ‘‘ask[ed] patients to waive the requirement
for a physical and to agree to have a physical before
taking a drug they purchase via the Internet.’’ Id.
In this regard, the Notice stated: ‘‘[a]n after-the-fact
physical does not take the place of establishing a
doctor/patient relationship. The physical exam
should take place before the prescription is
written.’’ Id.
VerDate Aug<31>2005
16:03 Dec 05, 2006
Jkt 211001
that such information was readily
available at the time Respondent
commenced his contract with
Pharmacon and therefore will not
excuse his misconduct.7 Moreover, I
find that Respondent’s experience in
dispensing controlled substances and
his record of compliance with
applicable laws involve numerous
violations of the CSA in that
Respondent issued prescriptions
without a legitimate medical purpose
and that these factors demonstrate that
granting Respondent’s application (in
the event the State were to rescind its
order) would be inconsistent with the
public interest. Having found so, it is
unnecessary to address the remaining
factors. See, e.g., Hoxie, 419 F.3d at 483;
Morall, 412 F.3d at 165.
Order
Accordingly, pursuant to the
authority vested in me by 21 U.S.C.
823(f), and 28 CFR 0.100(b) and 0.104,
I hereby order that the application of
Mario Alberto Diaz for a DEA Certificate
of Registration as a Practitioner be, and
it hereby is, denied. This order is
effective January 5, 2007.
Dated: November 3, 2006.
Michele M. Leonhart,
Deputy Administrator.
[FR Doc. E6–20630 Filed 12–5–06; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Foreign Claims Settlement
Commission
[F.C.S.C. Meeting Notice No. 10–06]
Sunshine Act Meeting Notice
The Foreign Claims Settlement
Commission, pursuant to its regulations
(45 CFR Part 504) and the Government
in the Sunshine Act (5 U.S.C. 552b),
hereby gives notice in regard to the
scheduling of meetings for the
transaction of Commission business and
other matters specified, as follows:
DATE AND TIME: Thursday, December 14,
2006, at 10 a.m.
SUBJECT MATTER: Issuance of Amended
Proposed Decisions and Amended Final
Decisions in claims against Albania.
STATUS: Open.
All meetings are held at the Foreign
Claims Settlement Commission, 600 E
7 I do not rely on the fact that Respondent worked
as an anesthesiologist after he surrendered his DEA
registration. While the administration of anesthesia
invariably requires the use of controlled substances
and it seems highly probable that Respondent
further violated the CSA by administering
controlled substances without a registration, this
conduct was not alleged in the Show Cause Order.
PO 00000
Frm 00060
Fmt 4703
Sfmt 4703
70793
Street, NW., Washington, DC. Requests
for information, or advance notices of
intention to observe an open meeting,
may be directed to: Administrative
Officer, Foreign Claims Settlement
Commission, 600 E Street, NW., Room
6002, Washington, DC 20579.
Telephone: (202) 616–6988.
Mauricio J. Tamargo,
Chairman.
[FR Doc. 06–9568 Filed 12–4–06; 10:10 am]
BILLING CODE 4410–01–P
DEPARTMENT OF LABOR
Office of the Secretary
Submission for OMB Review:
Comment Request
November 29, 2006.
The Department of Labor (DOL) has
submitted the following public
information collection request (ICR) to
the Office of Management and Budget
(OMB) for review and approval in
accordance with the Paperwork
Reduction Act of 1995 (Pub. L. 104–13,
44 U.S.C. chapter 35). A copy of this
ICR, with applicable supporting
documentation, may be obtained from
RegInfo.gov at https://www.reginfo.gov/
public/do/PRAMain or by contacting
Darrin King on 202–693–4129 (this is
not a toll-free number)/e-mail:
king.darrin@dol.gov.
Comments should be sent to Office of
Information and Regulatory Affairs,
Attn: OMB Desk Officer for the Bureau
of Labor Statistics (BLS), Office of
Management and Budget, Room 10235,
Washington, DC 20503, Telephone:
202–395–7316 / Fax: 202–395–6974
(these are not toll-free numbers), within
30 days from the date of this publication
in the Federal Register.
The OMB is particularly interested in
comments which:
• Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
• Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
• Enhance the quality, utility, and
clarity of the information to be
collected; and
• Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
E:\FR\FM\06DEN1.SGM
06DEN1
Agencies
[Federal Register Volume 71, Number 234 (Wednesday, December 6, 2006)]
[Notices]
[Pages 70788-70793]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-20630]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Mario Alberto Diaz, M.D.--Denial of Application
On June 27, 2005, the Deputy Assistant Administrator, Office of
[[Page 70789]]
Diversion Control, Drug Enforcement Administration, issued an Order to
Show Cause to Mario Alberto Diaz, M.D. (Respondent) of Miami, Florida.
The Show Cause Order proposed to deny Respondent's pending application
for a DEA Certificate of Registration as a practitioner, on the ground
that granting Respondent a registration would be inconsistent with the
public interest. See Show Cause Order at 1; see also 21 U.S.C.
824(a)(4), id. Sec. 823(f).
More specifically, the Show Cause Order alleged that in May 2003,
Respondent, who had previously been registered as a practitioner,
entered into a contract with Pharmacom, an Internet pharmacy, under
which he agreed to issue prescriptions online. Show Cause Order at 5.
The Show Cause Order alleged that Respondent issued approximately 100
prescriptions per day, and that Respondent admitted having issued
approximately twenty to twenty-five thousand prescriptions during the
period of his employment with Pharmacom. See id.
The Show Cause Order further alleged that Respondent issued
prescriptions for controlled substances based on questionnaires
submitted by customers over the Internet. See id. The Show Cause Order
alleged that the questionnaire solicited from the customer information
regarding the drugs the customer wished to purchase and obtained the
customer's payment information and was then electronically transmitted
to Respondent. See id. The Show Cause Order alleged that based on the
questionnaire, Respondent would issue a prescription for a controlled
substance and that the principal drugs he prescribed were hydrocodone,
a Schedule III controlled substance, and Valium, a Schedule IV
controlled substance. See id.
The Show Cause Order also alleged that Respondent never saw the
customers and did not perform a physical exam on them, that he did not
have a pre-existing doctor-patient relationship with them, and that he
did not create or maintain patient records for them. See id. The Show
Cause Order further alleged that Respondent never consulted with the
customers' primary care physicians or obtained from them the customers'
medical records, and that the only information he reviewed was the
questionnaires submitted by the customers. See id. at 5-6.
The Show Cause Order additionally alleged that many of the
prescriptions written by Respondent were for minors. See id. at 6. The
Show Cause Order also alleged that during its investigation of
Pharmacom, the Iowa Board of Pharmacy contacted approximately 20
customers who had received prescriptions for controlled substances that
were issued by Respondent. See id. The Show Cause Order alleged that
each of these customers told investigators that before receiving
controlled substances, they had had no contact with Respondent other
than by e-mail. Id. The Show Cause Order thus concluded by alleging
that Respondent was ``responsible for the diversion of large quantities
of controlled substances,'' and that he had ``indiscriminately
dispensed large volumes of controlled substances to persons'' he had
never seen or physically examined. Id.
On July 15, 2005, the Show Cause Order was served on Respondent by
certified mail as evidenced by the Return Receipt Card. Thereafter, on
July 23, 2005, Respondent submitted a letter to me in which he waived
his right to a hearing and submitted a written statement setting forth
his position on the matters of fact and law involved. See 21 CFR
1301.43(c). The investigative file was then forwarded to me for final
agency action.
Based on Respondent's letter to me, I conclude that Respondent has
waived his right to a hearing. Moreover, having considered the record
as a whole including Respondent's statement, I conclude that granting
Respondent's application for a new registration would be inconsistent
with the public interest and make the following findings.
Findings
Respondent, a medical doctor with a specialty in anesthesiology,
formerly held a DEA certificate of registration as a practitioner under
which he was authorized to prescribe Schedule II through Schedule V
controlled substances. On May 20, 2004, Respondent surrendered his
registration during the execution of a search warrant at his residence/
registered location, which was located in Miami, Florida.
On September 12, 2003, two DEA Diversion Investigators from the Des
Moines, Iowa office, DEA Task Force Officers, and investigators from
the Iowa Board of Pharmacy Examiners executed a federal search warrant
at the Union Family Pharmacy, 2541 Central Avenue, Dubuque, Iowa. The
search was initiated based on information that the Union Family
Pharmacy was engaged in filling purported prescriptions that it
downloaded from an Internet site and that it distributed the drugs to
persons nationwide.
During the search, investigators seized approximately twenty
thousand prescriptions that the pharmacy had filled and dispensed from
March 2003 through September 12, 2003, the date the warrant was
executed. Of these twenty thousand prescriptions, approximately five
thousand of them had been filled and dispensed on behalf of Pharmacom.
All of the Pharmacom prescriptions were filled between August 18, 2003,
and September 12, 2003.
The investigation determined that Pharmacom was located in Miami,
Florida, and that it owned the domain name Buymeds.com and operated the
Web site https://www.buymeds.com. Approximately 1,240 of the controlled
substance prescriptions downloaded by Union Family Pharmacy from the
Pharmacom web site and filled by the pharmacy were issued by
Respondent.
Because of unusual banking activity, Pharmacom had previously come
to the attention of the Internal Revenue Service (IRS) and, on
September 2, 2003, two IRS special agents interviewed Mr. Orlando
Birbragher, Pharmacom's President and CEO. During the interview, the
IRS special agents determined that Pharmacom operated multiple on-line
pharmacy Web sites including Buymeds.com. The interview determined that
Pharmacom's customers submitted on-line questionnaires to purchase
Schedule III and IV controlled substances, and that Pharmacom's doctors
evaluated the questionnaires to determine whether to approve or reject
the order. Pharmacom's doctors did not, however, conduct a physical
exam of the customer. Instead, the questionnaires required the patient
to indicate whether they had been examined by a physician within the
past year. Mr. Birbragher further maintained that Pharmacom's doctors
contacted the customers and their physicians when evaluating the
questionnaires. Those prescriptions which were approved were then sent
to a pharmacy, which filled the prescriptions and shipped them to the
customers. Pharmacom paid both the doctor who issued the prescription
and the pharmacy which filled it.
Mr. Birbragher told the IRS agents that Respondent had started
working for Pharmacom in March 2003. Respondent's duties involved
reviewing the questionnaires and determining whether a prescription
should be issued. Pharmacom initially paid Respondent $20 for
evaluating a request for a new prescription and $10 for evaluating a
request for a refill. Because of the volume of business it attracted,
Pharmacom subsequently cut its payment rates in half. Even at this
reduced payment rate, Pharmacom paid Respondent $218,586 between April
and August 2003. Mr. Birbragher further
[[Page 70790]]
told the IRS agents that Respondent used physician assistants (PA's) to
assist him in evaluating the patient questionnaires. Mr. Birbragher did
not know, however, whether Respondent or the PA's actually reviewed the
questionnaires.
Thereafter, one of the DIs reviewed prescription data obtained
during the search of the Union Family Pharmacy. More specifically, the
DI reviewed the prescription data that the pharmacy downloaded from the
buymeds.com website and filled on September 7, 2003. On that date, the
pharmacy filled 583 Buymeds' prescriptions. Of the 583 prescriptions,
only 29 (4.9%) were for non-controlled substances. The remaining
prescriptions were for controlled substances such as hydrocodone,
codeine, propoxyphene, and Ambien (zolpidem). Respondent issued 146 of
the 583 prescriptions that were filled that day. While the
investigative file does not indicate how many of these prescriptions
were for controlled substances, even if Respondent issued all of the
non-controlled substance prescriptions, he still would have issued 117
controlled substance prescriptions that were filled on that day.\1\
---------------------------------------------------------------------------
\1\ A further analysis of the computer data seized during the
search of the Union Family Pharmacy found that Respondent issued
1,240 prescriptions for controlled substances during the period
August 18, 2003, through September 12, 2003.
---------------------------------------------------------------------------
On May 20, 2004, investigators executed a search warrant at
Respondent's residence in Miami. While Respondent was not home when the
search commenced, his son contacted him by cell phone. Respondent spoke
with a DEA Special Agent and agreed to return to his residence. Upon
his return, a DI and IRS special agent interviewed him.
Respondent told the investigators that he began working for
Pharmacom in April 2003 and quit in November 2003. Respondent stated
that another physician had told him about Pharmacom's business and had
recommended him to Marshall Kanner, one of the owners. Thereafter,
Respondent interviewed with Kanner for a position with Pharmacom.
Kanner told him that the position would involve authorizing medication
over the Internet to patients who were seeing or had seen a doctor in
the past year. Respondent claimed that he expressed to Kanner his
concerns regarding prescribing medicine in this manner, but Kanner told
him it was legal. According to Respondent, Kanner also told him he
could authorize prescriptions for customers throughout the United
States.
Respondent told the investigators that customers would contact
Pharmacom through the Internet and fill out a questionnaire provided by
it. Pharmacom then assigned a list of patients to Respondent.
Respondent's job was to review the questionnaires and then interview
the customers either by telephone or e-mail to determine whether the
customers were eligible to receive the drug they requested.
Respondent stated to the investigators that he told Pharmacom that
he was only willing to review 100 customers a day and that he did not
issue prescriptions to ten to twenty-five percent of the customers.
Respondent also told the investigators that he reviewed approximately
40 to 50 refill prescriptions a day and that he made as much as $14,000
a week.
Respondent further told the investigators that he never saw any of
the customers and that he never developed a doctor/patient relationship
with any of them as everything was done either via the Internet or by
telephone. According to the DI's report, Respondent admitted that the
information provided by the customers was never verified and that when
he interviewed customers by telephone, he could not verify whom he was
talking to.
When the DI asked Respondent whether he knew it violated the law to
issue a prescription for a controlled substance without having a
legitimate doctor/patient relationship, Respondent did not give a
specific answer. Instead, Respondent asserted that whenever he
questioned the legality of the practice, Kanner or Birbragher assured
him that it was legal. When the DI reminded Respondent that he was the
doctor, Respondent stated, ``Yes, I know that.''
Respondent also told the investigators that he quit Pharmacom
because sometime in September or October 2003, Birbragher told him that
all customers would have to receive a physical exam and that he did not
agree with this policy. When questioned as to the basis of his
disagreement, Respondent became vague and evasive and would not
specifically answer the question. Towards the end of the interview,
Respondent was also advised by the DI that having surrendered his DEA
registration, he was not authorized to handle controlled substances in
any manner and could not possess, dispense, administer or prescribe
them.
Subsequently, on September 14, 2004, Respondent agreed to undergo a
proffer interview at the DEA Miami field office. During the interview,
at which he was represented by counsel, Respondent stated that he was
currently employed at a cosmetic surgery center where he provided
anesthesia services even though he had previously surrendered his DEA
registration.
During this interview, Respondent asserted that he had researched
the DEA w Web site and could not find any statute indicating that
prescribing over the Internet ``could not be done.'' Respondent further
stated that he thought the practice was similar to that in an emergency
room where the patients are ``unknown'' to the physician. Respondent
again maintained that he had contacted Kanner to determine whether the
practice was legal and had been told by Kanner that Pharmacom's
attorneys had ``stated that it was legal.'' Respondent further stated
that when he met with Kanner and Birbragher, they told him ``they were
licensed in all states and [that] he could make a huge amount of
money.''
Respondent further admitted that while he limited himself to 100
``patients'' per day, a general practitioner would normally see thirty
to forty patients per day. Respondent asserted that the only difference
between his activities and that of a general practitioner was that a
``general practitioner sees the patient.'' Respondent added that he
would review the medical history provided by the customer and such
other information as the customer's location, age, weight, height, and
previous and current medications. Later in this interview, Respondent
admitted that he ``felt uncomfortable with the number of patients'' he
was assigned, and that when he telephoned patients, ``some appeared to
be druggies.'' Respondent also stated that as time went on, he ``felt
people were ordering medications for habits or entertainment,'' and
that the ``types of people ordering were getting worse and worse.''
Respondent admitted that the customers submitted requests for
specific drugs, but that he would ``never ask a patient what drug they
wanted'' because doing so would be contrary to ``good medical
practice.'' He further stated that the ``best professional care would
be face to face.'' He also claimed that he had quit because the
physical examinations that Pharmacom had started providing were
incomplete.
Respondent admitted that some customers requested multiple drugs
such as hydrocodone and alprazolam. Respondent also stated that he
approved between twenty and twenty-five thousand prescriptions during
the period of his association with Pharmacom and that the highest
number of prescriptions he authorized in a day
[[Page 70791]]
was about 200. In response to a question regarding the danger of
prescribing medication without establishing a doctor/patient
relationship, Respondent stated that the ``potential for killing people
can happen in a hospital,'' but that ``a bigger potential [exists] over
the Internet.''
In his written statement responding to the Show Cause Order,
Respondent asserted that he ``attempted to perform my medical functions
in a professional and ethical manner.'' Respondent further stated that
he ``did call the patient to evaluate them for their prescriptions,''
and that he ``denied a high percentage of the prescriptions
requested.''
Respondent asserted that he searched the websites of both DEA and
the Florida Department of Health to see if there were ``any laws that
made this business illegal.'' Respondent also stated that Pharmacom's
owners had ``fooled [him] into thinking that their business was legal''
and that he ``would never knowingly violate any laws.'' Respondent
further asserted that he was unaware of the statements of DEA, the
American Medical Association, the Federation of State Medical Boards,
the Food and Drug Administration, and the National Association of
Boards of Pharmacy (all of which were recited in the Show Cause Order)
and all of which discuss the illegality and/or impropriety of
prescribing over the Internet without establishing a bona-fide doctor-
patient relationship.
Respondent contended that as an anesthesiologist he had rarely
written prescriptions and that while he ``knew that a patient-doctor
relationship had to be established,'' he ``honestly believed that
having a patient fill out a questionnaire about their health and
another dedicated section related to the medication they were
requesting would fulfill this criteria.'' Respondent also maintained
that he ``would question the patient about any previous prescriptions
for the medication they were then requesting,'' and that ``[a] very
large percentage of them had already been prescribed the medication by
their family physician.'' Respondent further stated that he ``did call
a few of their physicians in cases I suspected of problems.''
In his written statement, Respondent added that he resigned when he
became aware ``that a physical examination was needed to write a
prescription.'' Respondent also stated that he ``will never work for
any endeavor of this type ever again.'' Respondent concluded by stating
that he ``accept[ed] that the selling of medications over the Internet
is not correct and that a prescription should not be written without a
physical examination.''
I further take official notice of the fact that on May 17, 2006,
the Florida Department of Health issued an order imposing an emergency
suspension of Respondent's state medical license. That order remains in
effect.
Discussion
Section 303(f) of the Controlled Substances Act provides that an
application for a practitioner's registration may be denied upon a
determination ``that the issuance of such registration would be
inconsistent with the public interest.'' 21 U.S.C. 823(f). In making
the public interest determination, the Act requires the consideration
of the following factors:
(1) The recommendation of the appropriate State licensing board
or professional disciplinary authority.
(2) The applicant's experience in dispensing * * * controlled
substances.
(3) The applicant's conviction record under Federal or State
laws relating to the manufacture, distribution, or dispensing of
controlled substances.
(4) Compliance with applicable State, Federal, or local laws
relating to controlled substances.
(5) Such other conduct which may threaten the public health and
safety.
Id.
``[T]hese factors are * * * considered in the disjunctive,'' Robert
A. Leslie, M.D., 68 FR 15227, 15230 (2003). I ``may rely on any one or
combination of factors, and may give each factor the weight [I] deem[]
appropriate in determining whether * * * an application for
registration [should be] denied.'' Id. Moreover, case law establishes
that I am ``not required to make findings as to all of the factors.''
Hoxie v. DEA, 419 F.3d 477, 483 (6th Cir. 2005); see also Morall v.
DEA, 412 F.3d 165, 173-74 (D.C. Cir. 2005).
In this matter, I conclude that multiple grounds support the denial
of Respondent's application. Specifically, Respondent currently lacks
authority under Florida law to practice medicine and therefore is not
entitled to a DEA registration. Moreover, even if the State of Florida
were to rescind its order of emergency suspension, my analysis of
several other factors also demonstrates that granting his application
would be inconsistent with the public interest.
Factor One--The Recommendation of the State Licensing Board
It has long been recognized that ``[a]gencies may take official
notice of facts at any stage in a proceeding--even in the final
decision.'' U.S. Dept. of Justice, Attorney General's Manual on the
Administrative Procedure Act 80 (1947) (Wm. W. Gaunt & Sons, Inc.,
Reprint 1979). Therefore, pursuant to 5 U.S.C. 556(e) and 21 CFR Sec.
1316.59(e), I hereby take official notice of the fact that on May 17,
2006, the Florida Department of Health issued an order imposing an
emergency suspension of Respondent's state medical license.\2\
Respondent is therefore without authority under state law to handle
controlled substances in the state in which he intends to practice
medicine.
---------------------------------------------------------------------------
\2\ In accordance with the Administrative Procedure Act and
DEA's regulations, Respondent is ``entitled on timely request, to an
opportunity to show to the contrary.'' 5 U.S.C. 556(e). See also 21
CFR 1316.59(e). DEA's regulations contain no provision for
requesting reconsideration of a final order. See Robert A. Leslie,
M.D., 60 FR 14004, 14005 (1995). To allow Respondent the opportunity
to refute the facts of which I am taking official notice,
publication of this final order shall be withheld for a fifteen-day
period, which shall begin on the date of service by placing this
order in the mail.
---------------------------------------------------------------------------
Our precedents have repeatedly construed the Controlled Substances
Act (CSA) as precluding DEA from issuing a registration to an applicant
who lacks authority to handle controlled substances in the state where
the applicant practices medicine. See 21 U.S.C. 802(21) & 823(f); see
also George Thomas, 64 FR 15811, 15812 (1999); Robert E. Hales, 52 FR
17646 (1987). Moreover, denial of an application is appropriate even
``when a State license has been suspended, but [there is] a possibility
of future reactivitation.'' Alton E. Ingram, Jr., 69 FR 22562 (2004).
Therefore, I conclude that Respondent's lack of state authority is
reason alone to deny his application for a registration. But because
the Florida Department of Health's order is not a final decision and
may be rescinded, an analysis of Respondent's conduct as charged in the
Show Cause Order and his defenses is warranted.
Factors Two and Four--Respondent's Experience in Dispensing Controlled
Substances and His Record of Compliance With Applicable Laws
The CSA's implementing regulations state that for ``[a]
prescription for a controlled substance to be effective [it] must be
issued for a legitimate medical purpose by an individual practitioner
acting in the usual course of his professional practice.'' 21 CFR
1306.04(a). This regulation further provides that ``[a]n order
purporting to be a prescription issued not in the usual course of
professional treatment * * * is not a prescription within the meaning
and intent of * * * 21 U.S.C. 829 * * * and the person * * * issuing
it, shall be subject to the penalties provided for
[[Page 70792]]
violations of the provisions of law relating to controlled
substances.'' Id.
As the Supreme Court has recognized, the CSA reflects Congress's
``intent to limit a registered physician's dispensing authority to the
course of his professional practice.'' United States v. Moore, 423 U.S.
122, 140 (1975). The Court has further explained that the CSA
``reflect[s] the intent of Congress to confine authorized medical
practice within accepted limits.'' Id. at 141-42. Thus, in Moore, the
Court upheld a criminal conviction of a physician for knowingly or
intentionally distributing controlled substances in violation of the
CSA, explaining that the physician's ``conduct exceeded the bounds of
professional practice'' when the physician prescribed controlled
substances and ``gave inadequate physical examinations or none at
all.'' Id. at 142-43.
The evidence in this case establishes that Respondent repeatedly
acted outside the course of professional practice and violated the CSA.
Respondent, while contracted to Pharmacom, issued between twenty and
twenty-five thousand prescriptions to persons with whom he had no
bonafide doctor-patient relationship. While the investigative file does
not establish the exact number of controlled substance prescriptions
issued by Respondent, the analysis of the 583 Buymeds.com prescriptions
filled by Union Family Pharmacy on September 7, 2003, establishes that
at least 117 (out of a total of 143) prescriptions issued by Respondent
and filled on that date were for a controlled substance.\3\
Furthermore, the analysis of the prescriptions filled by the Union
Family Pharmacy for Pharmacom between August 18, 2003, and September
12, 2003, shows that Respondent issued 1240 controlled substance
prescriptions. Given that this represents only a small portion of the
period during which Respondent was engaged with Pharmacom, it is
reasonable to infer that Respondent issued many more prescriptions for
controlled substances.
---------------------------------------------------------------------------
\3\ The investigative file does not establish the precise date
that Respondent issued these prescriptions.
---------------------------------------------------------------------------
Respondent issued the prescriptions notwithstanding that he did not
perform a physical exam and had no face-to-face interaction with
Pharmacom's customers. While Respondent maintained that he called or
contacted via e-mail the customers ``on a regular basis'' to discuss
their questionnaires and denied some percentage of the requests,
Respondent admitted in the interviews that there was generally no way
to verify the information provided by the customers.\4\
---------------------------------------------------------------------------
\4\ I note, however, that Respondent does not contend that he
actually contacted every patient. Moreover, the assembly line nature
of his activity begs the question of what Respondent did when a
customer did not answer the phone or failed to timely call him back
or respond to his e-mail.
---------------------------------------------------------------------------
Furthermore, while Respondent asserts that he asked Pharmacom's
owners about the legality of issuing Internet prescriptions (who
assured him that the practice was lawful), there were numerous reasons
to question its legality. For example, customers were not required to
submit any documentation (other than the questionnaire) regarding a
medical condition that would demonstrate the need for a drug.\5\
Moreover, Respondent did not review the customer's questionnaires and
choose a drug to prescribe based on his ``diagnosis'' of the customer's
medical condition. Rather, it was the customer who requested a specific
drug. Respondent admitted, however, that he would ``never ask a patient
what drug they wanted'' because doing so would be contrary to ``good
medical practice.''
---------------------------------------------------------------------------
\5\ This is not to suggest that Respondent would have acted
lawfully if he had issued prescriptions on the basis of medical
reports submitted directly to him by customers.
---------------------------------------------------------------------------
Finally, Respondent should have questioned why Pharmacom's
customers did not submit prescriptions issued by their own doctors but
rather required that prescriptions be issued by him and the other
Pharmacom doctors. Indeed, Respondent admitted that when he telephoned
patients, ``some appeared to be druggies,'' and that as time went on he
``felt people were ordering medications for habits or entertainment.''
In short, Respondent had numerous indications that issuing
prescriptions in this manner ``exceeded the bounds of professional
practice,'' Moore, 423 U.S. at 142, and violated federal law
notwithstanding the comments of Pharmacom's owners.
Respondent maintains that he visited the DEA and Florida Department
of Health Web sites but could find no information that the practice of
Internet prescribing was illegal. As for his effort to find information
on the issue at the DEA Web site, Respondent must not have looked very
hard. On April 27, 2001, DEA published a Notice in the Federal Register
entitled ``Dispensing and Purchasing Controlled Substances over the
Internet.'' See 66 FR 21181. To the extent DEA was required to give
notice of this policy statement, publication in the Federal Register is
all that was necessary to comply with the Administrative Procedure Act.
See 5 U.S.C. 552(a)(1)(D). DEA, however, took the further step of
posting this policy statement on the Office of Diversion Control's Web
page and the document is easily found by using the Web page's search
engine.
The purpose of the Notice was ``to provide guidance to prescribers
* * * and the public concerning the application of current laws and
regulations as they relate to the use of the Internet for dispensing
[and] purchasing * * * controlled substances.'' Id. The Notice further
explained that ``[w]ith the advent of Internet pharmacies, DEA
registrants and the public have asked how these Internet pharmacies fit
into the requirements that currently exist for the prescribing and
dispensing of controlled substances.'' Thus, DEA issued this policy
statement, which was based on the application of existing law to the
new circumstances that arose with the emergence of the Internet as a
mechanism to engage in commerce.
The Notice expressly addressed the potential illegality under
existing law of prescribing a controlled substance based on an on-line
questionnaire. After noting the regulation pertaining to the purpose of
a prescription, see 21 CFR 1306.04, the Notice explained that ``[u]nder
Federal and state law, for a doctor to be acting in the usual course of
professional practice, there must be a bona fide doctor/patient
relationship.'' 66 FR at 21182. The Notice further observed that:
many state authorities, with the endorsement of medical societies,
consider the existence of the following four elements as an
indication that a legitimate doctor/patient relationship has been
established:
A patient has a medical complaint
A medical history has been taken
A physical examination has been performed; and
Some logical connection exists between the medical
complaint, the medical history, the physical examination, and the
drug prescribed.
Id. at 21182-83.
The Notice thus concluded that ``[c]ompleting a questionnaire that
is then reviewed by a doctor hired by the Internet pharmacy could not
be considered the basis for a doctor/patient relationship. * * * It is
illegal to receive a prescription for a controlled substance without
the establishment of a legitimate doctor/patient relationship, and it
is unlikely for such a relationship to be formed through Internet
correspondence alone.'' \6\ Id. at 21183.
---------------------------------------------------------------------------
\6\ As the Notice explained, ``[a] consumer can more easily
provide false information in a questionnaire than in a face-to-face
meeting with a doctor.'' Id. at 21183.
The Notice also discussed some Internet sites which ``ask[ed]
patients to waive the requirement for a physical and to agree to
have a physical before taking a drug they purchase via the
Internet.'' Id. In this regard, the Notice stated: ``[a]n after-the-
fact physical does not take the place of establishing a doctor/
patient relationship. The physical exam should take place before the
prescription is written.'' Id.
---------------------------------------------------------------------------
[[Page 70793]]
The Notice further stated that doctors who issued prescriptions
without establishing a legitimate doctor/patient relationship could be
subjected ``to criminal, civil, or administrative actions,'' and that
``[f]or DEA registrants administrative action may include the loss of
their DEA registration.'' Id. Thus, contrary to Respondent's suggestion
that no information was publicly available regarding the potential
illegality of the practice, DEA had given fair warning that prescribing
a controlled substance based on an on-line questionnaire and without
conducting a physical exam could be deemed a violation of the CSA's
longstanding requirement that a prescription must be issued for a
legitimate medical purpose. DEA also warned that issuing a prescription
without such a purpose could subject a physician to criminal, civil and
administrative proceedings.
Moreover, in April 2002, the Federation of State Medical Boards
adopted its model guidelines for the use of the Internet in medical
practice. Section Five of this document states that ``[a] documented
patient evaluation, including history and physical evaluation adequate
to establish diagnoses and identify underlying conditions and/or
contra-indications to the treatment recommended/provided, must be
obtained prior to providing treatment, including issuing prescriptions,
electronically or otherwise.'' Federation of State Medical Boards of
the U.S., Inc., Model Guidelines for the Appropriate Use of the
Internet in Medical Practice 5 (2002) (emphasis added).
The guidelines further state that ``[t]reatment and consultation
recommendations made in an online setting, including issuing a
prescription via electronic means, will be held to the same standards
of appropriate practice as those in traditional (face-to-face)
settings.'' Id. Finally, the guidelines state that ``[t]reatment,
including issuing a prescription, based solely on an online
questionnaire or consultation, does not constitute an acceptable
standard of care.'' Id.
Thus, while Respondent may have lacked actual knowledge of DEA's
interpretation of the CSA and the position of other entities involved
in the regulation of his profession, I conclude that such information
was readily available at the time Respondent commenced his contract
with Pharmacon and therefore will not excuse his misconduct.\7\
Moreover, I find that Respondent's experience in dispensing controlled
substances and his record of compliance with applicable laws involve
numerous violations of the CSA in that Respondent issued prescriptions
without a legitimate medical purpose and that these factors demonstrate
that granting Respondent's application (in the event the State were to
rescind its order) would be inconsistent with the public interest.
Having found so, it is unnecessary to address the remaining factors.
See, e.g., Hoxie, 419 F.3d at 483; Morall, 412 F.3d at 165.
---------------------------------------------------------------------------
\7\ I do not rely on the fact that Respondent worked as an
anesthesiologist after he surrendered his DEA registration. While
the administration of anesthesia invariably requires the use of
controlled substances and it seems highly probable that Respondent
further violated the CSA by administering controlled substances
without a registration, this conduct was not alleged in the Show
Cause Order.
---------------------------------------------------------------------------
Order
Accordingly, pursuant to the authority vested in me by 21 U.S.C.
823(f), and 28 CFR 0.100(b) and 0.104, I hereby order that the
application of Mario Alberto Diaz for a DEA Certificate of Registration
as a Practitioner be, and it hereby is, denied. This order is effective
January 5, 2007.
Dated: November 3, 2006.
Michele M. Leonhart,
Deputy Administrator.
[FR Doc. E6-20630 Filed 12-5-06; 8:45 am]
BILLING CODE 4410-09-P